{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:07Z","timestamp":1792707667073,"version":"4.5.0"},"publisher-location":"New York, NY","reference-count":60,"publisher":"Springer New York","isbn-type":[{"value":"9781493973736","type":"print"},{"value":"9781493973743","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7374-3_10","type":"book-chapter","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T07:08:50Z","timestamp":1508828930000},"page":"143-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Designing Effective Antisense Oligonucleotides for Exon Skipping"],"prefix":"10.1007","author":[{"given":"Takenori","family":"Shimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"issue":"3","key":"10_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176. doi:\n                    10.3390\/jpm3030144","journal-title":"J Pers Med"},{"issue":"13","key":"10_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. doi:\n                    10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"issue":"6","key":"10_CR3","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.4049\/jimmunol.176.6.3652","volume":"176","author":"TA Vickers","year":"2006","unstructured":"Vickers TA, Zhang H, Graham MJ, Lemonidis KM, Zhao C, Dean NM (2006) Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2\u2032-O-methoxyethyl-modified oligonucleotide. J Immunol 176(6):3652\u20133661","journal-title":"J Immunol"},{"key":"10_CR4","unstructured":"(2016) Eteplirsen (Exondys 51) for duchenne muscular dystrophy. Med Lett Drugs Ther 58(1507):145\u2013146"},{"issue":"7","key":"10_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N, Motoki H, Miyazaki D, Nishizawa H, Echigoya Y, Yokota T, Aoki Y, Takeda S (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663\u2013667. doi:\n                    10.1038\/jhg.2016.28","journal-title":"J Hum Genet"},{"issue":"4","key":"10_CR6","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M, Kaariainen H, de la Chapellet A, Kiuru A, Savontaus ML, Gilgenkrantz H, Recan D, Chelly J, Kaplan JC, Covone AE, Archidiacono N, Romeo G, Liechti-Gailati S, Schneider V, Braga S, Moser H, Darras BT, Murphy P, Francke U, Chen JD, Morgan G, Denton M, Greenberg CR, Wrogemann K, Blonden LA, van Paassen MB, van Ommen GJ, Kunkel LM (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45(4):498\u2013506","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Shiba N, Miyazaki D, Nishizawa H, Inaba Y, Fueki N, Maruyama R, Echigoya Y, Yokota T (2016) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463. doi:\n                    10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"3","key":"10_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. doi:\n                    10.1002\/humu.20918","journal-title":"Hum Mutat"},{"issue":"12","key":"10_CR9","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K, Yoshida T, Tomita E, Waki R, Yamamoto T, Doi T, Inoue T, Kawakami J, Obika S (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. doi:\n                    10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle A, Griffith G, Babbs A, El Andaloussi S, Ezzat K, Avril A, Dugovic B, Chaussenot R, Ferry A, Voit T, Amthor H, Buhr C, Schurch S, Wood MJ, Davies KE, Vaillend C, Leumann C, Garcia L (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 21(3):270\u2013275. doi:\n                    10.1038\/nm.3765","journal-title":"Nat Med"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/nass\/48.1.297","volume":"48","author":"M Takagi","year":"2004","unstructured":"Takagi M, Yagi M, Ishibashi K, Takeshima Y, Surono A, Matsuo M, Koizumi M (2004) Design of 2\u2032-O-Me RNA\/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic Acids Symp Ser (Oxf) 48:297\u2013298. doi:\n                    10.1093\/nass\/48.1.297","journal-title":"Nucleic Acids Symp Ser (Oxf)"},{"key":"10_CR12","doi-asserted-by":"publisher","unstructured":"Miskew Nichols B, Aoki Y, Kuraoka M, Lee JJ, Takeda S, Yokota T (2016) Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy. J Vis Exp 111. doi:\n                    10.3791\/53776","DOI":"10.3791\/53776"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. doi:\n                    10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"10_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667\u2013676. doi:\n                    10.1002\/ana.21627","journal-title":"Ann Neurol"},{"key":"10_CR15","volume-title":"Morpholino oligos","author":"R Maruyama","year":"2016","unstructured":"Maruyama R, Aoki Y, Echigoya Y, Caluseriu O, Takeda S, Yokota T (2016) Morpholino-mediated multi-exon skipping in dystrophic dogs. In: Moulton H, Moulton J (eds) Morpholino oligos. Humana Press, New York. vol In Press"},{"issue":"5","key":"10_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/nat.2012.0368","volume":"22","author":"T Yokota","year":"2012","unstructured":"Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22(5):306\u2013315. doi:\n                    10.1089\/nat.2012.0368","journal-title":"Nucleic Acid Ther"},{"issue":"24","key":"10_CR17","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22(24):4914\u20134928. doi:\n                    10.1093\/hmg\/ddt341","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/humu.21160","volume":"31","author":"N Wein","year":"2010","unstructured":"Wein N, Avril A, Bartoli M, Beley C, Chaouch S, Laforet P, Behin A, Butler-Browne G, Mouly V, Krahn M, Garcia L, Levy N (2010) Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 31(2):136\u2013142. doi:\n                    10.1002\/humu.21160","journal-title":"Hum Mutat"},{"issue":"6","key":"10_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. doi:\n                    10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"issue":"7367","key":"10_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature10456","volume":"478","author":"M Taniguchi-Ikeda","year":"2011","unstructured":"Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu CC, Mori K, Oda T, Kuga A, Kurahashi H, Akman HO, DiMauro S, Kaji R, Yokota T, Takeda S, Toda T (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478(7367):127\u2013131. doi:\n                    10.1038\/nature10456","journal-title":"Nature"},{"issue":"3","key":"10_CR21","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.ddstr.2013.06.002","volume":"10","author":"L Spraggon","year":"2013","unstructured":"Spraggon L, Cartegni L (2013) Antisense modulation of RNA processing as a therapeutic approach in cancer therapy. Drug Discov Today Ther Strateg 10(3):e139\u2013e148. doi:\n                    10.1016\/j.ddstr.2013.06.002","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"43","key":"10_CR22","doi-asserted-by":"publisher","first-page":"17779","DOI":"10.1073\/pnas.1108482108","volume":"108","author":"F Zammarchi","year":"2011","unstructured":"Zammarchi F, de Stanchina E, Bournazou E, Supakorndej T, Martires K, Riedel E, Corben AD, Bromberg JF, Cartegni L (2011) Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A 108(43):17779\u201317784. doi:\n                    10.1073\/pnas.1108482108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nm.3106","volume":"19","author":"JJ Lentz","year":"2013","unstructured":"Lentz JJ, Jodelka FM, Hinrich AJ, McCaffrey KE, Farris HE, Spalitta MJ, Bazan NG, Duelli DM, Rigo F, Hastings ML (2013) Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nat Med 19(3):345\u2013350. doi:\n                    10.1038\/nm.3106","journal-title":"Nat Med"},{"issue":"6","key":"10_CR24","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/nar\/gkv163","volume":"43","author":"A Wojtkowiak-Szlachcic","year":"2015","unstructured":"Wojtkowiak-Szlachcic A, Taylor K, Stepniak-Konieczna E, Sznajder LJ, Mykowska A, Sroka J, Thornton CA, Sobczak K (2015) Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res 43(6):3318\u20133331. doi:\n                    10.1093\/nar\/gkv163","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10_CR25","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1172\/JCI82768","volume":"125","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, Wyatt E, Goldstein JA, LoPresti P, Castillo LM, Gazda A, Petrossian N, Earley JU, Hadhazy M, Barefield DY, Demonbreun AR, Bonnemann C, Wolf M, McNally EM (2015) Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest 125(11):4186\u20134195. doi:\n                    10.1172\/JCI82768","journal-title":"J Clin Invest"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-4-431-55678-7_6","volume-title":"Translational research in muscular dystrophy","author":"JJA Lee","year":"2016","unstructured":"Lee JJA, Yokota T (2016) Translational research in nucleic acid therapies for muscular dystrophies. In: Takeda S, Miyagoe-suzuki Y, Mori-Yoshimura M (eds) Translational research in muscular dystrophy, 1st edn. Springer, Tokyo, pp 87\u2013102. doi:\n                    10.1007\/978-4-431-55678-7","edition":"1st"},{"issue":"9","key":"10_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acn3.96","volume":"1","author":"JA Dominov","year":"2014","unstructured":"Dominov JA, Uyan O, Sapp PC, McKenna-Yasek D, Nallamilli BR, Hegde M, Brown RH Jr (2014) A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. Ann Clin Transl Neurol 1(9):703\u2013720. doi:\n                    10.1002\/acn3.96","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7(3):187\u2013195","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"8","key":"10_CR29","first-page":"1314","volume":"7","author":"X Yu","year":"2015","unstructured":"Yu X, Bao B, Echigoya Y, Yokota T (2015) Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res 7(8):1314\u20131331","journal-title":"Am J Transl Res"},{"issue":"1","key":"10_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102(1):198\u2013203. doi:\n                    10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10_CR31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM (2016) Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86(10):890\u2013897. doi:\n                    10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"issue":"1","key":"10_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada S, Yokota T (2016) Current translational research and murine models for duchenne muscular dystrophy. J Neuromuscul Dis 3(1):29\u201348","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10_CR33","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1093\/nar\/gkm358","volume":"35","author":"CJ Yang","year":"2007","unstructured":"Yang CJ, Wang L, Wu Y, Kim Y, Medley CD, Lin H, Tan W (2007) Synthesis and investigation of deoxyribonucleic acid\/locked nucleic acid chimeric molecular beacons. Nucleic Acids Res 35(12):4030\u20134041. doi:\n                    10.1093\/nar\/gkm358","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10_CR34","doi-asserted-by":"publisher","first-page":"e0120058","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L, Yokota T, Duddy W (2015) In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10(3):e0120058. doi:\n                    10.1371\/journal.pone.0120058","journal-title":"PLoS One"},{"issue":"3","key":"10_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2008.205","volume":"17","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, de Kimpe S, van Deutekom JC, t Hoen PA, van Ommen GJ (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17(3):548\u2013553. doi:\n                    10.1038\/mt.2008.205","journal-title":"Mol Ther"},{"issue":"1","key":"10_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/archneurol.2008.540","volume":"66","author":"T Yokota","year":"2009","unstructured":"Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66(1):32\u201338","journal-title":"Arch Neurol"},{"issue":"8","key":"10_CR37","doi-asserted-by":"publisher","first-page":"e12239","DOI":"10.1371\/journal.pone.0012239","volume":"5","author":"T Saito","year":"2010","unstructured":"Saito T, Nakamura A, Aoki Y, Yokota T, Okada T, Osawa M, Takeda S (2010) Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 5(8):e12239. doi:\n                    10.1371\/journal.pone.0012239","journal-title":"PLoS One"},{"issue":"1","key":"10_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/nat.2013.0451","volume":"24","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57\u201368. doi:\n                    10.1089\/nat.2013.0451","journal-title":"Nucleic Acid Ther"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"402369","DOI":"10.1155\/2013\/402369","volume":"2013","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Yokota T, Wood MJ (2013) Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int 2013:402369. doi:\n                    10.1155\/2013\/402369","journal-title":"Biomed Res Int"},{"issue":"9","key":"10_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y, Kolski H (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141\u20131152. doi:\n                    10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135\u2013144","journal-title":"Muscle Nerve"},{"issue":"9","key":"10_CR42","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gkp215","volume":"37","author":"FO Desmet","year":"2009","unstructured":"Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C (2009) Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37(9):e67. doi:\n                    10.1093\/nar\/gkp215","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"10_CR43","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","volume":"31","author":"M Zuker","year":"2003","unstructured":"Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31(13):3406\u20133415","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"10_CR44","doi-asserted-by":"publisher","first-page":"W43","DOI":"10.1093\/nar\/gkm234","volume":"35","author":"WA Kibbe","year":"2007","unstructured":"Kibbe WA (2007) OligoCalc: an online oligonucleotide properties calculator. Nucleic Acids Res 35(Web Server issue):W43\u2013W46. doi:\n                    10.1093\/nar\/gkm234","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/nar\/30.1.38","volume":"30","author":"T Hubbard","year":"2002","unstructured":"Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T, Cuff J, Curwen V, Down T, Durbin R, Eyras E, Gilbert J, Hammond M, Huminiecki L, Kasprzyk A, Lehvaslaiho H, Lijnzaad P, Melsopp C, Mongin E, Pettett R, Pocock M, Potter S, Rust A, Schmidt E, Searle S, Slater G, Smith J, Spooner W, Stabenau A, Stalker J, Stupka E, Ureta-Vidal A, Vastrik I, Clamp M (2002) The Ensembl genome database project. Nucleic Acids Res 30(1):38\u201341","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10_CR46","doi-asserted-by":"publisher","first-page":"D717","DOI":"10.1093\/nar\/gkv1275","volume":"44","author":"ML Speir","year":"2016","unstructured":"Speir ML, Zweig AS, Rosenbloom KR, Raney BJ, Paten B, Nejad P, Lee BT, Learned K, Karolchik D, Hinrichs AS, Heitner S, Harte RA, Haeussler M, Guruvadoo L, Fujita PA, Eisenhart C, Diekhans M, Clawson H, Casper J, Barber GP, Haussler D, Kuhn RM, Kent WJ (2016) The UCSC genome browser database: 2016 update. Nucleic Acids Res 44(D1):D717\u2013D725. doi:\n                    10.1093\/nar\/gkv1275","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10_CR47","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14712598.7.6.831","volume":"7","author":"T Yokota","year":"2007","unstructured":"Yokota T, Pistilli E, Duddy W, Nagaraju K (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 7(6):831\u2013842. doi:\n                    10.1517\/14712598.7.6.831","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10_CR48","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26(3):179\u2013184","journal-title":"Acta Myol"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-61737-982-6_20","volume":"709","author":"T Yokota","year":"2011","unstructured":"Yokota T, Hoffman E, Takeda S (2011) Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 709:299\u2013312. doi:\n                    10.1007\/978-1-61737-982-6_20","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nmd.2013.09.004","volume":"24","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM, Voit T, Rosales XQ, Servais L, Kraus JE, Wardell C, Morgan A, Dorricott S, Nakielny J, Quarcoo N, Liefaard L, Drury T, Campion G, Wright P (2014) Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord 24(1):16\u201324. doi:\n                    10.1016\/j.nmd.2013.09.004","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10_CR51","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","volume":"13","author":"T Voit","year":"2014","unstructured":"Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, Liefaard L, Lourbakos A, Morgan A, Nakielny J, Quarcoo N, Ricotti V, Rolfe K, Servais L, Wardell C, Wilson R, Wright P, Kraus JE (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13(10):987\u2013996. doi:\n                    10.1016\/S1474-4422(14)70195-4","journal-title":"Lancet Neurol"},{"issue":"5","key":"10_CR52","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM, Eteplirsen Study G (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637\u2013647. doi:\n                    10.1002\/ana.23982","journal-title":"Ann Neurol"},{"issue":"1","key":"10_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.mt.6300006","volume":"15","author":"PL Harding","year":"2007","unstructured":"Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD (2007) The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 15(1):157\u2013166. doi:\n                    10.1038\/sj.mt.6300006","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"10_CR54","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1186\/1471-2105-10-S1-S33","volume":"10","author":"CY Chan","year":"2009","unstructured":"Chan CY, Carmack CS, Long DD, Maliyekkel A, Shao Y, Roninson IB, Ding Y (2009) A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinformatics 10(Suppl 1):S33. doi:\n                    10.1186\/1471-2105-10-S1-S33","journal-title":"BMC Bioinformatics"},{"issue":"34","key":"10_CR55","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109(34):13763\u201313768. doi:\n                    10.1073\/pnas.1204638109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10_CR56","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.1093\/nar\/gkv857","volume":"43","author":"PJ Kamola","year":"2015","unstructured":"Kamola PJ, Kitson JD, Turner G, Maratou K, Eriksson S, Panjwani A, Warnock LC, Douillard Guilloux GA, Moores K, Koppe EL, Wixted WE, Wilson PA, Gooderham NJ, Gant TW, Clark KL, Hughes SA, Edbrooke MR, Parry JD (2015) In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res 43(18):8638\u20138650. doi:\n                    10.1093\/nar\/gkv857","journal-title":"Nucleic Acids Res"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"30377","DOI":"10.1038\/srep30377","volume":"6","author":"T Kasuya","year":"2016","unstructured":"Kasuya T, Hori S, Watanabe A, Nakajima M, Gahara Y, Rokushima M, Yanagimoto T, Kugimiya A (2016) Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides. Sci Rep 6:30377. doi:\n                    10.1038\/srep30377","journal-title":"Sci Rep"},{"issue":"13","key":"10_CR58","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1093\/nar\/gkg580","volume":"31","author":"N Tolstrup","year":"2003","unstructured":"Tolstrup N, Nielsen PS, Kolberg JG, Frankel AM, Vissing H, Kauppinen S (2003) OligoDesign: optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. Nucleic Acids Res 31(13):3758\u20133762","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10_CR59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/hum.2013.234","volume":"25","author":"P Disterer","year":"2014","unstructured":"Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, Khoo B (2014) Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 25(7):587\u2013598. doi:\n                    10.1089\/hum.2013.234","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10_CR60","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1093\/nar\/19.11.2979","volume":"19","author":"L Kibler-Herzog","year":"1991","unstructured":"Kibler-Herzog L, Zon G, Uznanski B, Whittier G, Wilson WD (1991) Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res 19(11):2979\u20132986","journal-title":"Nucleic Acids Res"}],"container-title":["Methods in Molecular Biology","Duchenne Muscular Dystrophy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7374-3_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T03:49:28Z","timestamp":1558064968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7374-3_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"ISBN":["9781493973736","9781493973743"],"references-count":60,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7374-3_10","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,25]]},"assertion":[{"value":"25 October 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}